Efficacy and safety of meropenem (3g/day) in the treatment of severe/refractory respiratory infections
Not Applicable
- Conditions
- severe/refractory respiratory infections
- Registration Number
- JPRN-UMIN000011835
- Lead Sponsor
- Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who had been treated with meropenem 2.Contraindication for meropenem 3.Liver insufficiency (elevated levels of AST/ALT more than 5 times of the upper limits) 4.Renal insufficiency (elevated levels of BUN/creatinine more than 2 times of the upper limits) 5.Patients anticipating being susceptive of convulsion after brain disorders 6.Patients deemed ineligible by the attending physicians for various reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method